- In September 2024, Boehringer Ingelheim International GmbH announced that the FIBRONEER-IPF trial met its primary endpoint of FVC improvement at week 52, and it plans to submit a new drug application for nerandomilast for IPF treatment to the FDA and other global authorities. This successful trial and upcoming submission will strengthen Boehringer Ingelheim’s position in the competitive IPF market, potentially expanding its respiratory drug portfolio
- In July 2024, Teva and Sanofi announced an updated timeline for the anti-TL1A program, duvakitug, a monoclonal antibody targeting TL1A for moderate-to-severe IBD. Advancing this program strengthens both companies’ positions in the IBD treatment market, potentially expanding their offerings in immunology
- In November 2022, Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced a new collaboration with Rimidi, a leading clinical management platform designed to optimize clinical workflows, enhance patient experiences and achieve quality objectives. This has helped the company to expand globally
- In March 2022, Genentech, a member of the Roche Group announced that the Phase III SKYSCRAPER-02 study, evaluating the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq (atezolizumab) and chemotherapy (carboplatin and etoposide) as an initial (first-line) treatment for people with extensive-stage small cell lung cancer (ES-SCLC), did not meet its co-primary endpoint of progression-free survival. This has helped the company to expand globally
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
5 MIDDLE EAST AND AFRICA FIBROTIC DISEASES TREATMENT MARKET, REGULATIONS
5.1 NORTH AMERICA
5.1.1 U.S.
5.1.2 CANADA
5.2 EUROPE
5.2.1 EUROPEAN UNION (EMA - EUROPEAN MEDICINES AGENCY)
5.2.2 GERMANY (FEDERAL INSTITUTE FOR DRUGS AND MEDICAL DEVICES - BFARM)
5.2.3 UNITED KINGDOM (MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY - MHRA)
5.3 ASIA-PACIFIC
5.3.1 JAPAN (PMDA - PHARMACEUTICALS AND MEDICAL DEVICES AGENCY)
5.3.2 CHINA (NMPA - NATIONAL MEDICAL PRODUCTS ADMINISTRATION)
5.3.3 AUSTRALIA (TGA - THERAPEUTIC GOODS ADMINISTRATION)
5.4 LATIN AMERICA
5.4.1 BRAZIL (ANVISA - BRAZILIAN HEALTH REGULATORY AGENCY)
5.4.2 ARGENTINA (ADMINISTRACIÓN NACIONAL DE MEDICAMENTOS, ALIMENTOS Y TECNOLOGÍA MÉDICA - ANMAT)
5.5 MIDDLE EAST AND AFRICA (MEA)
5.5.1 UNITED ARAB EMIRATES (UAE - MINISTRY OF HEALTH AND PREVENTION)
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISING PREVALENCE OF FIBROTIC DISEASES
6.1.2 INCREASE IN THE NUMBER OF PEOPLE SMOKING CIGARETTES
6.1.3 TECHNOLOGICAL ADVANCEMENT IN THE TREATMENT OF FIBROSIS DISEASES
6.1.4 AWARENESS AND EARLY DIAGNOSIS INITIATIVES
6.2 RESTRAINTS
6.2.1 HIGH COST OF MEDICATION AND TREATMENTS
6.2.2 LACK OF EFFECTIVE BIOMARKERS AND DIAGNOSTIC TOOLS FOR EARLY DETECTION AND MONITORING OF FIBROTIC DISEASES
6.3 OPPORTUNITIES
6.3.1 RISING RESEARCH AND DEVELOPMENT ACTIVITIES
6.3.2 ADVANCEMENTS IN PIPELINE DRUG DEVELOPMENTS
6.3.3 INCREASING STRATEGIC COLLABORATIONS AND PARTNERSHIPS
6.4 CHALLENGES
6.4.1 THE COMPLEX AND MULTIFACTORIAL NATURE OF FIBROTIC DISEASES.
6.4.2 HIGH RATE OF FAILURE IN CLINICAL TRIALS FOR FIBROTIC DISEASES,
7 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT
7.1 OVERVIEW
7.2 MEDICATION
7.2.1 MEDICATION, BY TREATMENT
7.2.2 MEDICATION, BY DISTRIBUTION CHANNEL
7.3 ORGAN TRANSPLANT
7.4 OXYGEN THERAPY
7.5 OTHERS
8 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION
8.1 OVERVIEW
8.2 IDIOPATHIC PULMONARY FIBROSIS
8.3 HEPATIC CIRRHOSIS
8.4 RENAL FIBROSIS
8.5 CUTANEOUS FIBROSIS
8.6 OTHERS
9 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY END USER
9.1 OVERVIEW
9.2 HOSPITALS
9.3 SPECIALTY CLINICS
9.4 ACADEMIC AND RESEARCH INSTITUTES
9.5 OTHERS
10 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY REGION
10.1 MIDDLE EAST AND AFRICA
11 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, COMPANY LANDSCAPE
11.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
12 SWOT ANALYSIS
13 COMPANY PROFILE
13.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
13.1.1 COMPANY SNAPSHOT
13.1.2 REVENUE ANALYSIS
13.1.3 COMPANY SHARE ANALYSIS
13.1.4 PRODUCT PORTFOLIO
13.1.5 RECENT DEVELOPMENTS
13.2 GENENTECH, INC. (A SUBSIDIARY OF F. HOFFMANN-LA ROCHE LTD)
13.2.1 COMPANY SNAPSHOT
13.2.2 COMPANY SHARE ANALYSIS
13.2.3 PRODUCT PORTFOLIO
13.2.4 RECENT DEVELOPMENTS
13.3 TEVA PHARMACEUTICAL INDUSTRIES LTD.
13.3.1 COMPANY SNAPSHOT
13.3.2 REVENUE ANALYSIS
13.3.3 COMPANY SHARE ANALYSIS
13.3.4 PRODUCT PORTFOLIO
13.3.5 RECENT DEVELOPMENTS
13.4 SANDOZ INTERNATIONAL GMBH
13.4.1 COMPANY SNAPSHOT
13.4.2 COMPANY SHARE ANALYSIS
13.4.3 PRODUCT PORTFOLIO
13.4.4 RECENT DEVELOPMENTS
13.5 ACCORD HEALTHCARE
13.5.1 COMPANY SNAPSHOT
13.5.2 COMPANY SHARE ANALYSIS
13.5.3 PRODUCT PORTFOLIO
13.5.4 RECENT DEVELOPMENTS
13.6 ABBVIE INC.
13.6.1 COMPANY SNAPSHOT
13.6.2 REVENUE ANALYSIS
13.6.3 PRODUCT PORTFOLIO
13.6.4 RECENT DEVELOPMENTS
13.7 BRISTOL-MYERS SQUIBB COMPANY.
13.7.1 COMPANY SNAPSHOT
13.7.2 REVENUE ANALYSIS
13.7.3 PRODUCT PORTFOLIO
13.7.4 RECENT DEVELOPMENTS
13.8 BIOMX.
13.8.1 COMPANY SNAPSHOT
13.8.2 PRODUCT PORTFOLIO
13.8.3 RECENT DEVELOPMENTS
13.9 INTERCEPT PHARMACEUTICALS, INC.
13.9.1 COMPANY SNAPSHOT
13.9.2 REVENUE ANALYSIS
13.9.3 PRODUCT PORTFOLIO
13.9.4 RECENT DEVELOPMENTS
13.1 KITHER BIOTECH S.R.L.
13.10.1 COMPANY SNAPSHOT
13.10.2 PRODUCT PORTFOLIO
13.10.3 RECENT DEVELOPMENTS
13.11 REDX PHARMA PLC.
13.11.1 COMPANY SNAPSHOT
13.11.2 REVENUE ANALYSIS
13.11.3 PRODUCT PORTFOLIO
13.11.4 RECENT DEVELOPMENTS
13.12 VERONA PHARMA PLC
13.12.1 COMPANY SNAPSHOT
13.12.2 REVENUE ANALYSIS
13.12.3 PRODUCT PORTFOLIO
13.12.4 RECENT DEVELOPMENTS
14 QUESTIONNAIRE
15 RELATED REPORTS
List of Table
TABLE 1 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 2 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 3 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 4 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2018-2032 (VOLUME)
TABLE 5 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2018-2032 (ASP)
TABLE 6 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 7 MIDDLE EAST AND AFRICA ORGAN TRANSPLANT IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 8 MIDDLE EAST AND AFRICA OXYGEN THERAPY IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 9 MIDDLE EAST AND AFRICA OTHERS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 10 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 11 MIDDLE EAST AND AFRICA IDIOPATHIC PULMONARY FIBROSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 12 MIDDLE EAST AND AFRICA HEPATIC CIRRHOSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 13 MIDDLE EAST AND AFRICA RENAL FIBROSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 14 MIDDLE EAST AND AFRICA CUTANEOUS FIBROSIS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 15 MIDDLE EAST AND AFRICA OTHERS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 16 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 17 MIDDLE EAST AND AFRICA HOSPITALS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 18 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 19 MIDDLE EAST AND AFRICA ACADEMIC AND RESEARCH INSTITUTES IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 20 MIDDLE EAST AND AFRICA OTHER END-USE IN FIBROTIC DISEASE TREATMENT MARKET, BY REGION, 2018-2032 (USD THOUSAND)
TABLE 21 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)
TABLE 22 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 23 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 24 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 25 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 26 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 27 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 28 MIDDLE EAST AND AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 29 SOUTH AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 30 SOUTH AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 31 SOUTH AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 32 SOUTH AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 33 SOUTH AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 34 SOUTH AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 35 SOUTH AFRICA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 36 SAUDI ARABIA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 37 SAUDI ARABIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 38 SAUDI ARABIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 39 SAUDI ARABIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 40 SAUDI ARABIA FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 41 SAUDI ARABIA FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 42 SAUDI ARABIA MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 43 U.A.E. FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 44 U.A.E. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 45 U.A.E. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 46 U.A.E. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 47 U.A.E. FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 48 U.A.E. FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 49 U.A.E. MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 50 EGYPT FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 51 EGYPT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 52 EGYPT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 53 EGYPT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 54 EGYPT FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 55 EGYPT FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 56 EGYPT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 57 KUWAIT FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 58 KUWAIT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 59 KUWAIT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 60 KUWAIT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 61 KUWAIT FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 62 KUWAIT FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 63 KUWAIT MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 64 ISRAEL FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 65 ISRAEL MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 66 ISRAEL MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 67 ISRAEL MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 68 ISRAEL FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 69 ISRAEL FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 70 ISRAEL MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 71 BAHRAIN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 72 BAHRAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
TABLE 73 BAHRAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (VOLUME)
TABLE 74 BAHRAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (ASP)
TABLE 75 BAHRAIN FIBROTIC DISEASE TREATMENT MARKET, BY APPLICATION, 2018-2032 (USD THOUSAND)
TABLE 76 BAHRAIN FIBROTIC DISEASE TREATMENT MARKET, BY END USER, 2018-2032 (USD THOUSAND)
TABLE 77 BAHRAIN MEDICATION IN FIBROTIC DISEASE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2032 (USD THOUSAND)
TABLE 78 REST OF MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET, BY TREATMENT, 2018-2032 (USD THOUSAND)
List of Figure
FIGURE 1 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: SEGMENTATION
FIGURE 11 EXECUTIVE SUMMARY
FIGURE 12 STRATEGIC DECISIONS
FIGURE 13 INCREASING PREVALENCE OF CHRONIC DISEASES IS DRIVING THE GROWTH OF THE MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET FROM 2025 TO 2032
FIGURE 14 THE MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET IN 2025 AND 2032
FIGURE 15 MARKET OVERVIEW
FIGURE 16 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2024
FIGURE 17 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, 2025-2032 (USD THOUSAND)
FIGURE 18 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, CAGR (2025-2032)
FIGURE 19 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE
FIGURE 20 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, 2024
FIGURE 21 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, 2025-2032 (USD THOUSAND)
FIGURE 22 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, CAGR (2025-2032)
FIGURE 23 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 24 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY END USER, 2024
FIGURE 25 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY END USER, 2025-2032 (USD THOUSAND)
FIGURE 26 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY END USER, CAGR (2025-2032)
FIGURE 27 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 28 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: SNAPSHOT (2024)
FIGURE 29 MIDDLE EAST AND AFRICA FIBROTIC DISEASE TREATMENT MARKET: COMPANY SHARE 2024 (%)
